USE OF ORLISTAT IN PREGNANCY
Date of issue: August 2026, Version: 5
Orlistat is an orally administered gastric and pancreatic lipase inhibitor which reduces the absorption of dietary fat. It is used in conjunction with dietary measures to enhance weight loss in adults who are overweight (BMI ≥25). Systemic absorption of orlistat is expected to be negligible.
Maternal obesity has been associated with increased risks of adverse maternal and fetal outcomes, including congenital malformations. Weight loss prior to pregnancy is therefore strongly encouraged for women with obesity who are planning a pregnancy. However, the National Institute of Health and Care Excellence (NICE) states that intentional weight loss during pregnancy is not recommended. Orlistat should therefore be discontinued upon recognition of pregnancy.
The available data regarding orlistat use in pregnancy, although too limited to form definitive conclusions, do not indicate increased risks of fetal malformations or miscarriage. Other outcomes (preterm delivery, low birth weight, stillbirth and neonatal complication risks) have been studied in women with preconceptual exposure to orlistat, with no concern of increased risks. While orlistat is minimally absorbed from the gastrointestinal tract, it may impair the absorption of fat-soluble vitamins (A, D, E, and K); therefore, there are theoretical concerns that its use during pregnancy may restrict nutrient availability to the fetus.
As data relating to orlistat use in pregnancy are limited, an earlier fetal anomaly scan (from 16 weeks of pregnancy) could be considered following exposure in the first trimester. Other risk factors which independently increase the risk of adverse pregnancy outcome may be present in individual cases. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.
This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.
If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.
If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.